0000000001323331

AUTHOR

F. Zipp

showing 3 related works from this author

Vemurafenib and cobimetinib combination therapy for BRAFV600E-mutated melanoma favors posterior reversible encephalopathy syndrome

2019

OncologyCobimetinibmedicine.medical_specialtyCombination therapybusiness.industryMelanomaPosterior reversible encephalopathy syndromeHematologymedicine.diseasechemistry.chemical_compoundText miningOncologychemistryInternal medicinemedicineVemurafenibbusinessmedicine.drugAnnals of Oncology
researchProduct

Neuroprotektive Ansätze in der Neurologie – Enttäuschte Hoffnungen?

2013

Drug DiscoveryGeneral MedicineDrug Research
researchProduct

Supplementary Material for: Targeting Voltage-Dependent Calcium Channels with Pregabalin Exerts a Direct Neuroprotective Effect in an Animal Model of…

2018

Background/Aims: Multiple sclerosis (MS) is a prototypical autoimmune central nervous system (CNS) disease. Particularly progressive forms of MS (PMS) show significant neuroaxonal damage as consequence of demyelination and neuronal hyperexcitation. Immuno-modulatory treatment strategies are beneficial in relapsing MS (RMS), but mostly fail in PMS. Pregabalin (Lyrica®) is prescribed to MS patients to treat neuropathic pain. Mechanistically, it targets voltage-dependent Ca2+ channels and reduces harmful neuronal hyperexcitation in mouse epilepsy models. Studies suggest that GABA analogues like pregabalin exert neuroprotective effects in animal models of ischemia and trauma. Methods: We tested…

researchProduct